Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05942937
Other study ID # VISP2101
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 4, 2023
Est. completion date December 2024

Study information

Verified date March 2024
Source Kirby Institute
Contact Andrew Lloyd
Phone 02 9385 2534
Email a.lloyd@unsw.edu.au
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The National Prisons Hepatitis Education Program (HepPEd Program) is a national, prison-based hepatitis C health literacy education program for healthcare providers, correctional officers, and people in prison. The HepPEd Program aims to improve the public health literacy of the prison sector regarding hepatitis C in prisons. The HepPEd: Research Evaluation aims to evaluate the impact of the HepPEd Program on HCV testing and treatment uptake amongst people incarcerated in Australian prisons, as well as changes in knowledge, attitudes, and capabilities of healthcare providers, correctional officers, and people in prison. The study is a controlled before and after study being conducted in 3-6 correctional centres in Australia.


Description:

The National Prisons Hepatitis Education Program (HepPEd Program) is a national, prison-based hepatitis C health literacy education program for healthcare providers, correctional officers, and people in prison. The broad goal of HepPEd: Research Evaluation is to measure the impact of a prison-specific hepatitis C (HCV) education program (the HepPEd Program) on enhancing HCV testing and treatment rates in Australian prisons. The HepPEd Program aims to improve HCV testing and treatment rates by enhancing the public health literacy of the prison sector regarding HCV in the prisons (that is the knowledge, attitudes and behaviours), and specifically targets the three key audience groups from the prison setting: healthcare providers, correctional officers, and people in prison. The study will be conducted as a prison-level, controlled before-and-after trial with a primary objective of evaluating the impact of the HepPEd Program on HCV treatment uptake amongst people incarcerated in Australian prisons. Three to six Australian correctional centres will be selected to participate in the 9-month study. Each correctional centre will have a 3-month period of pre-intervention surveillance, involving monthly observation of HCV treatment uptake under existing operations. This will be followed by a three-month period of education delivery of the HepPEd Program (the 'education intervention'). The monthly surveillance data collection will continue during the intervention period. Finally, each correctional centre will have another 3-month period of post-intervention surveillance, again involving monthly surveillance of HCV treatment rates. Surveys will be conducted with members from each target audience group before and after the education intervention and dried blood spot testing will be conducted with members from the people in prison group to assess baseline HCV prevalence before the education intervention.


Recruitment information / eligibility

Status Recruiting
Enrollment 3000
Est. completion date December 2024
Est. primary completion date July 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility All healthcare providers, correctional officers, and people in prison at the participating prison sites are anticipated to be exposed to the various HepPEd Program resources during the 3 month education intervention phase. Participating prison sites must meet the following inclusion criteria to be eligible to participate in the study. Participating prison sites must have: - a prisoner population of 400-600 inmates (assumed mean 500); and - an existing prison-based hepatitis service undertaking both HCV testing and treatment. Prisoners must meet the following inclusion criteria to be eligible to participate as peer educators. Prisoners must: - be currently incarcerated in a participating correctional centre; - anticipate being in the participating correctional centre for >12 months; - be considered as capable and willing, and well-respected amongst their peers; and - have approval from custodial authorities to participate as a peer educator. Correctional officers must meet the following inclusion criteria to be eligible to participate as peer champions. Correctional officers must: - be currently working in a participating correctional centre; and - be considered as capable and willing, and well-respected amongst their peers. Prisoners must meet the following inclusion criteria to be eligible to participate in the interview-style survey and dried blood spot (DBS) testing component: 1. be over the age of 18 years; 2. be currently incarcerated in a participating correctional centre; 3. have sufficient English comprehension skills to understand the survey questions; and 4. be willing and able to provide written informed consent. Healthcare providers and correctional officers must meet the following inclusion criteria to be eligible to participate in the survey component: 1) be currently working in a participating correctional centre.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Education Intervention (The HepPEd Program)
All healthcare providers, correctional officers, and people in prison (HepPEd Program target audience groups) at each participating site are anticipated to be exposed to the HepPEd Program over the course of the three-month education intervention phase. The HepPEd Program involves a suite of multi-modal resources targeting each target audience group and a peer education program (for correctional officer and people in prison groups only). The HepPEd Program resources will be delivered in an informal, mass education-style, as well as in peer to peer format.

Locations

Country Name City State
Australia Risdon Prison Complex Hobart Tasmania
Australia Capricornia Correctional Centre Rockhampton Queensland

Sponsors (3)

Lead Sponsor Collaborator
Kirby Institute Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM), Justice health, corrections, and hepatitis and drug-user organisations in each Australian state and territory

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary The change in the proportion of prisoners treated for HCV before and after the education intervention. This will be measured by calculating the change in HCV treatment rates before and after the education intervention. 9 months from baseline
Secondary The proportion of prisoners tested for HCV before and after the education intervention. This will be measured by calculating the change in HCV testing rates before and after the education intervention. 9 months from baseline
Secondary The health literacy (knowledge, attitudes, and capabilities) amongst target audience groups (healthcare providers, correctional officers, and people in prison) before and after the education intervention. This will be measured by assessing the change in health literacy before and after the education intervention. 9 months from baseline
Secondary The acceptability, utility, and impact of the HepPEd Program. This is measured by surveys, before and after the education intervention. 9 months from baseline
Secondary The dose, reach, and fidelity of the HepPEd Program. This is measured by surveys, before and after the education intervention. 9 months from baseline
See also
  Status Clinical Trial Phase
Completed NCT02604017 - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection Phase 3
Completed NCT01221298 - A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) Phase 2
Recruiting NCT05794646 - Community Intervention to Eliminate HCV Among People Who Use Drugs. N/A
Completed NCT04971330 - Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol
Completed NCT02247401 - Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt Phase 3
Completed NCT02833298 - Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening N/A
Active, not recruiting NCT03981445 - Integrated HIV Prevention and HCV Care for PWID N/A
Completed NCT02452814 - Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection N/A
Recruiting NCT05904470 - A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Phase 2
Not yet recruiting NCT06316739 - The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City N/A
Completed NCT02116543 - TD-6450 MAD Study in HCV Infected Subjects Phase 1
Recruiting NCT05454579 - The South-East Asian Transgender Health Cohort
Active, not recruiting NCT03221309 - Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
Completed NCT03801707 - Utilization of Hepatitis C Positive Kidneys in Negative Recipients Phase 2/Phase 3
Not yet recruiting NCT03820102 - Impact of Metabolic Changes and Vitamin D Status on Virological Response in Patients With HCV Infection Treated by DAAs
Completed NCT01074008 - A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 Phase 2
Completed NCT05616598 - Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters Phase 2/Phase 3
Recruiting NCT05854511 - Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children Phase 3
Completed NCT03069001 - Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV Phase 4
Completed NCT01842451 - A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C Phase 2